Free Trial
NASDAQ:AZN

AstraZeneca (AZN) Stock Price, News & Analysis

$78.42
-0.89 (-1.12%)
(As of 06/18/2024 ET)
Today's Range
$78.38
$79.09
50-Day Range
$68.11
$80.83
52-Week Range
$60.47
$80.86
Volume
3.82 million shs
Average Volume
3.67 million shs
Market Capitalization
$243.14 billion
P/E Ratio
38.44
Dividend Yield
2.46%
Price Target
$88.00

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
12.2% Upside
$88.00 Price Target
Short Interest
Healthy
0.22% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.69mentions of AstraZeneca in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.59%
From $4.04 to $4.67 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.24 out of 5 stars

Medical Sector

333rd out of 913 stocks

Pharmaceutical Preparations Industry

156th out of 430 stocks

AZN stock logo

About AstraZeneca Stock (NASDAQ:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Price History

AZN Stock News Headlines

[Urgent] Protect your money before November
Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.
[Urgent] Protect your money before November
Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.
3 No-Brainer Stocks to Buy in June
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/25 Dividend
2/22/2024
Dividend Payable
3/25/2024
Last Earnings
4/25/2024
Today
6/18/2024
Next Earnings (Estimated)
7/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AZN
Employees
89,900
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$88.00
High Stock Price Target
$97.00
Low Stock Price Target
$82.00
Potential Upside/Downside
+12.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$5.96 billion
Pretax Margin
15.62%

Debt

Sales & Book Value

Annual Sales
$45.81 billion
Cash Flow
$5.32 per share
Book Value
$12.63 per share

Miscellaneous

Outstanding Shares
3,100,470,000
Free Float
N/A
Market Cap
$243.14 billion
Optionable
Optionable
Beta
0.48

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in AstraZeneca:

  • AstraZeneca's recent partnership with a leading biotech company for the development of a groundbreaking cancer treatment has the potential to significantly boost the company's revenue and market share in the oncology sector.
  • The company's strong pipeline of innovative drugs, including the latest generation of respiratory and cardiovascular medications, positions AstraZeneca well for sustained growth and profitability in the pharmaceutical industry.
  • Recent positive clinical trial results for AstraZeneca's COVID-19 vaccine have enhanced the company's reputation and could lead to increased demand for its other pharmaceutical products.
  • AstraZeneca's current stock price is trading at an attractive valuation compared to its peers in the healthcare sector, offering investors a potential opportunity for capital appreciation.
  • The company's strategic focus on expanding its presence in emerging markets presents a long-term growth opportunity as these regions continue to experience rising healthcare expenditures and demand for pharmaceutical products.

Cons

Investors should be bearish about investing in AstraZeneca for these reasons:

  • AstraZeneca faces potential regulatory challenges and legal risks related to product safety and marketing practices, which could lead to financial penalties and damage to the company's reputation.
  • The competitive landscape in the pharmaceutical industry is intense, with increasing pressure on pricing and market access, posing a threat to AstraZeneca's revenue growth and profitability margins.
  • Fluctuations in currency exchange rates can impact AstraZeneca's financial performance, especially in markets where the company generates a significant portion of its revenue, leading to earnings volatility.
  • Concerns about patent expirations for some of AstraZeneca's key drugs may result in generic competition, affecting the company's market share and revenue streams in the near term.
  • The ongoing challenges in drug development and regulatory approvals could lead to delays in product launches, impacting AstraZeneca's ability to capitalize on market opportunities and meet revenue targets.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, May 29, 2024. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AZN Stock Analysis - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AZN shares.
View AZN analyst ratings
or view top-rated stocks.

What is AstraZeneca's stock price target for 2024?

9 analysts have issued 12 month target prices for AstraZeneca's shares. Their AZN share price targets range from $82.00 to $97.00. On average, they anticipate the company's share price to reach $88.00 in the next year. This suggests a possible upside of 12.2% from the stock's current price.
View analysts price targets for AZN
or view top-rated stocks among Wall Street analysts.

How have AZN shares performed in 2024?

AstraZeneca's stock was trading at $67.35 at the start of the year. Since then, AZN stock has increased by 16.4% and is now trading at $78.42.
View the best growth stocks for 2024 here
.

Are investors shorting AstraZeneca?

AstraZeneca saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 6,670,000 shares, a drop of 13.0% from the May 15th total of 7,670,000 shares. Based on an average trading volume of 5,120,000 shares, the days-to-cover ratio is currently 1.3 days.
View AstraZeneca's Short Interest
.

When is AstraZeneca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, July 26th 2024.
View our AZN earnings forecast
.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) posted its earnings results on Thursday, April, 25th. The company reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.08. The firm had revenue of $12.68 billion for the quarter, compared to analyst estimates of $11.92 billion. AstraZeneca had a trailing twelve-month return on equity of 30.42% and a net margin of 13.30%.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a Semi-Annual dividend on Thursday, February 8th. Shareholders of record on Friday, February 23rd will be paid a dividend of $0.965 per share on Monday, March 25th. This represents a dividend yield of 2.3%. The ex-dividend date is Thursday, February 22nd. This is a positive change from the stock's previous Semi-Annual dividend of $0.47.
Read our dividend analysis for AZN
.

Is AstraZeneca a good dividend stock?

AstraZeneca (NASDAQ:AZN) pays an annual dividend of $1.93 per share and currently has a dividend yield of 2.43%. The dividend payout ratio is 94.61%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, AZN will have a dividend payout ratio of 41.33% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AZN.

When did AstraZeneca's stock split?

AstraZeneca shares split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Pascal Soriot's approval rating as AstraZeneca's CEO?

2,350 employees have rated AstraZeneca Chief Executive Officer Pascal Soriot on Glassdoor.com. Pascal Soriot has an approval rating of 98% among the company's employees. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. 87.0% of employees surveyed would recommend working at AstraZeneca to a friend.

What other stocks do shareholders of AstraZeneca own?
Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (1.98%), Capital International Investors (1.11%), Jennison Associates LLC (0.56%), Capital World Investors (0.30%), Clearbridge Investments LLC (0.10%) and WCM Investment Management LLC (0.10%).
View institutional ownership trends
.

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AstraZeneca have any subsidiaries?
The following companies are subsidiares of AstraZeneca: AAPM Sar, AZ Reinsurance Limited, AZ-Mont Insurance Company, AZENCO2 Limited, AZENCO4 Limited, Acerta Pharma B.V., Acerta Pharma LLC, AcertaPharma, Aktiebolaget Hassle, Alexion Pharmaceuticals, Almirall, AlphaCore Pharma, Amylin Ohio LLC, Amylin Pharmaceuticals LLC, Archigen Biotech Limited, Ardea Biosciences, Ardea Biosciences Limited, Arrow Therapeutics, Arrow Therapeutics Limited, Aspire Therapeutics B.V., Astra Alpha Produtos Farmaceuticos Lda, Astra Export & Trading Aktiebolag, Astra Lakemedel Aktiebolag, Astra Pharmaceuticals Limited, Astra Tech International Aktiebolag, AstraPharm, AstraZeneca (Israel) Ltd, AstraZeneca (Thailand) Limited, AstraZeneca (Wuxi) Trading Co. Ltd, AstraZeneca A/S, AstraZeneca AB, AstraZeneca AG, AstraZeneca AS, AstraZeneca Asia-Pacific Business Services Sdn Bhd, AstraZeneca B.V., AstraZeneca BioVentureHub AB, AstraZeneca Biotech AB, AstraZeneca Bulgaria EOOD, AstraZeneca CAMCAR Costa Rica S.A., AstraZeneca CAMCAR S.A., AstraZeneca Canada Inc., AstraZeneca China UK Limited, AstraZeneca Collaboration Ventures LLC, AstraZeneca Colombia S.A.S., AstraZeneca Continent B.V., AstraZeneca Czech Republic s.r.o., AstraZeneca Death In Service, AstraZeneca Dunkerque Production SCS, AstraZeneca Eesti OÜ, AstraZeneca Egypt for Pharmaceutical Industries JSC, AstraZeneca Egypt for Trading LLC, AstraZeneca Employee Share Trust Limited, AstraZeneca FZ-LLC, AstraZeneca Farmaceutica Chile Limitada, AstraZeneca Farmaceutica Holding Spain S.A., AstraZeneca Farmaceutica Spain S.A., AstraZeneca Finance Limited, AstraZeneca Finance S.A.S., AstraZeneca Gamma B.V., AstraZeneca GmbH, AstraZeneca Health Care Division S.A. de C.V., AstraZeneca Holding Aktiebolag, AstraZeneca Holding France S.A.S., AstraZeneca Holding GmbH, AstraZeneca Holdings B.V., AstraZeneca Holdings Pty Limited, AstraZeneca Hong Kong Limited, AstraZeneca Ilac Sanayi ve Ticaret Limited Sirketi, AstraZeneca India Private Limited, AstraZeneca Industries LLC, AstraZeneca Intermediate Holdings Limited, AstraZeneca International Holdings Aktiebolag, AstraZeneca Investment (China) Co. Ltd, AstraZeneca Investments Limited, AstraZeneca Japan Limited, AstraZeneca Jota B.V., AstraZeneca K.K., AstraZeneca Kft, AstraZeneca Korea Co. Ltd, AstraZeneca Latvija SIA, AstraZeneca Lietuva UAB, AstraZeneca Limited, AstraZeneca Luxembourg S.A., AstraZeneca Maroc SARLAU, AstraZeneca Nigeria Limited, AstraZeneca Nominees Limited, AstraZeneca Nordic AB, AstraZeneca OY., AstraZeneca PTY Limited, AstraZeneca Pars Company, AstraZeneca Peru S.A., AstraZeneca Pharma India Limited, AstraZeneca Pharma Poland Sp.z.o.o., AstraZeneca Pharma S.R.L., AstraZeneca Pharmaceutical (China) Co. Ltd, AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company, AstraZeneca Pharmaceuticals (Phils.) Inc., AstraZeneca Pharmaceuticals (Pty) Limited, AstraZeneca Pharmaceuticals Aktiebolag, AstraZeneca Pharmaceuticals Co. Limited, AstraZeneca Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, AstraZeneca Pharmaceuticals Limited, AstraZeneca Pharmaceuticals Pakistan (Private) Limited, AstraZeneca Pharmaceuticals Technologies (Beijing) Co. Ltd, AstraZeneca Produtos Farmaceuticos Lda, AstraZeneca Quest Limited, AstraZeneca Rho B.V., AstraZeneca S.A., AstraZeneca S.A. / N.V., AstraZeneca S.A. de C.V., AstraZeneca S.A.S., AstraZeneca Sdn Bhd, AstraZeneca Share Trust Limited, AstraZeneca Sigma B.V., AstraZeneca Singapore Pte Limited, AstraZeneca SpA, AstraZeneca Sweden Investments Limited, AstraZeneca Södertälje 2 AB, AstraZeneca Taiwan Limited, AstraZeneca Treasury B.V., AstraZeneca Treasury Limited, AstraZeneca Tunisie SaRL, AstraZeneca UK Limited, AstraZeneca US Investments Limited, AstraZeneca Ukraina LLC, AstraZeneca Venezuela S.A., AstraZeneca Vietnam Company Limited, AstraZeneca Zeta B.V, AstraZeneca d.o.o, AstraZeneca do Brasil Limitada, AstraZeneca Österreich GmbH, Atkemix Nine Inc., Atkemix Ten Inc., BMS Holdco Inc., Cambridge Antibody Technology, Cambridge Antibody Technology Group Limited, Centus Biotherapeutics Limited, Corpus Christi Holdings Inc., Definiens GmbH, Definiens Inc., Drimex LLC, Gotland Pharma S.A., Guangdong BeiKang Pharmaceutical Company Ltd, IPR Pharmaceuticals Inc., KuDOS Horsham Limited, KuDOS Pharmaceuticals Limited, KuDOS Pharmaceuticals Ltd, Laboratorio Beta S.A., Laboratorio Lailan S.A., Laboratorio Odin S.A., Laboratorio Tau S.A., MedImmune LLC, MedImmune Limited, MedImmune Pharma B.V, MedImmune U.K. Limited, MedImmune Ventures Inc, Montrose Chemical Corporation of California, Novastra Promoção e Comércio Farmacêutico Lda, Novastuart Produtos Farmaceuticos Lda, Novexel, Omthera Pharmaceuticals, Omthera Pharmaceuticals Inc., Optein Inc., P.T. AstraZeneca Indonesia, Pearl Therapeutics, Pearl Therapeutics Inc, Pharmaceutical Manufacturing Company Pty Limited, Pharmaceutical Manufacturing Division Pty Limited, SPA AstraZeneca Al Djazair, Simesa SpA, Sofotec GmbH, Spirogen Sarl, Stauffer Management Company LLC, Stuart Pharma Aktiebolag, Stuart-Produtos Farmacêuticos Lda, Symbicom Aktiebolag, Takeda Respiratory Business, Tika Lakemedel Aktiebolag, Trustee Limited, Unipessoal Lda, WuXi MedImmune Biopharmaceutical Co, ZS Pharma, ZS Pharma Inc, Zenco (No. 8) Limited, Zeneca Epsilon – Produtos Farmacêuticos Lda, Zeneca Finance (Netherlands) Company, Zeneca Holdings Inc., Zeneca Ilac Sanayi Ve Ticaret Anonim Sirketi, Zeneca Inc., Zeneca Wilmington Inc., and Zenecapharma Produtos Farmaceuticos .
Read More
This page (NASDAQ:AZN) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners